Zacks Research Has Positive View of Medifast FY2026 Earnings

Medifast logo with Consumer Staples background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research raised its FY2026 EPS forecast to a loss of $0.52 per share from a loss of $1.04, but maintained a “Hold” rating. The revised estimate is close to the analyst consensus of a $0.57 loss.
  • Medifast’s latest quarter beat expectations, reporting a loss of $0.19 per share versus the $0.35 forecast and revenue of $72.05 million versus the $71.30 million estimate.
  • Analyst sentiment remains cautious: MarketBeat reports a consensus “Reduce” rating and a $12 average price target, while Zacks’ forecasts project losses in FY2027 and FY2028.
  • Five stocks we like better than Medifast.

Medifast Inc (NYSE:MED - Free Report) - Zacks Research increased their FY2026 earnings per share estimates for Medifast in a research report issued to clients and investors on Monday, November 16th. Zacks Research analyst Team now anticipates that the specialty retailer will post earnings of ($0.52) per share for the year, up from their previous estimate of ($1.04). Zacks Research has a "Hold" rating on the stock. The consensus estimate for Medifast's current full-year earnings is ($0.57) per share. Zacks Research also issued estimates for Medifast's Q4 2026 earnings at $0.14 EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.56) EPS, Q1 2028 earnings at ($0.15) EPS, Q3 2028 earnings at ($0.33) EPS and FY2028 earnings at ($0.49) EPS.

Medifast (NYSE:MED - Get Free Report) last announced its earnings results on Monday, October 26th. The specialty retailer reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.16. Medifast had a negative return on equity of 6.90% and a negative net margin of 13.64%. The firm had revenue of $72.05 million during the quarter, compared to analyst estimates of $71.30 million.

Separately, Weiss Ratings lowered shares of Medifast from a "sell (d)" rating to a "sell (d-)" rating in a research report on Wednesday, October 28th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Reduce" and an average target price of $12.00.

Get Our Latest Report on MED

Medifast Price Performance

NYSE MED opened at $12.22 on Wednesday. The business's fifty day moving average is $12.15 and its 200-day moving average is $11.40. The stock has a market capitalization of $136.66 million, a price-to-earnings ratio of -3.31 and a beta of 0.65. Medifast has a one year low of $9.22 and a one year high of $13.63.

Hedge Funds Weigh In On Medifast

Institutional investors and hedge funds have recently bought and sold shares of the company. Ancora Advisors LLC raised its stake in Medifast by 411.5% in the 3rd quarter. Ancora Advisors LLC now owns 36,110 shares of the specialty retailer's stock valued at $416,000 after acquiring an additional 29,050 shares during the period. Marshall Wace LLP lifted its holdings in Medifast by 46.0% during the third quarter. Marshall Wace LLP now owns 352,704 shares of the specialty retailer's stock valued at $4,063,000 after purchasing an additional 111,055 shares during the last quarter. Advisors Asset Management Inc. purchased a new stake in Medifast during the third quarter valued at about $106,000. Commons Capital LLC lifted its holdings in Medifast by 23.0% during the third quarter. Commons Capital LLC now owns 184,432 shares of the specialty retailer's stock valued at $2,125,000 after purchasing an additional 34,516 shares during the last quarter. Finally, Engineers Gate Manager LP boosted its position in Medifast by 25.9% during the second quarter. Engineers Gate Manager LP now owns 49,829 shares of the specialty retailer's stock worth $529,000 after purchasing an additional 10,249 shares during the period. 95.51% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Daniel R. Chard sold 9,545 shares of Medifast stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $11.98, for a total value of $114,349.10. Following the sale, the director owned 140,153 shares of the company's stock, valued at approximately $1,679,032.94. The trade was a 6.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Parsa Kiai purchased 43,150 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was bought at an average cost of $12.26 per share, for a total transaction of $529,019.00. Following the acquisition, the director directly owned 707,492 shares in the company, valued at $8,673,851.92. This trade represents a 6.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 96,847 shares of company stock valued at $1,158,138 over the last three months. Insiders own 3.70% of the company's stock.

Medifast News Roundup

Investors following MED have been watching these news items:

  • Positive Sentiment: Zacks raised its FY2026 EPS estimate to a loss of $0.52 from a loss of $1.04, and its Q4 2026 estimate to earnings of $0.14 from a loss of $0.17. It also modestly improved its Q1 2028 estimate to a loss of $0.15 from $0.16.
  • Neutral Sentiment: Zacks maintained a “Hold” rating on Medifast.
  • Negative Sentiment: Most revisions were cuts: estimates for FY2027 and FY2028 were lowered to losses of $0.56 and $0.49 per share, respectively. Forecasts for multiple quarters in 2027 and Q3 2028 were also reduced, including Q3 2028 to a loss of $0.33 from $0.09. The broader pattern of weaker projected earnings could weigh on investor sentiment.

About Medifast

(Get Free Report)

Medifast, Inc. is a health and wellness company focused on weight management and healthy living. Its products and programs are marketed primarily under the OPTAVIA brand. OPTAVIA offers structured plans that combine portion-controlled meal replacements and other nutrition products with guidance from independent coaches. The company's approach emphasizes nutrition, behavior changes and ongoing support. Founded in 1980, Medifast serves customers primarily in the United States. Its business centers on selling products and connecting customers with coaches who provide support as they follow the company's programs.

See Also

Earnings History and Estimates for Medifast (NYSE:MED)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medifast Right Now?

Before you consider Medifast, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.

While Medifast currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines